Biological and in Silico Studies on the Benzimidazole-Based Compounds

ArticleAçık Erişim

Özet

Two 1,2-disubstituted benzimidazole-based compounds (2 and 3) were synthesized in this study. The antiproliferative activities of these compounds 1-(4-methylbenzyl)-2-p-tolyl-1H-benzo[d]imidazole (2), 1-(3-methoxybenzyl)-2-p-tolyl-1H-benzo[d]imidazole (3) together with cisplatin as a positive control drug were performed by the MTT method against the MDA-MB-231 breast cancer cell line. Compound 2 exhibited relatively higher cytotoxic activity. Molecular docking studies of compounds were performed against five breast cancer targets (PARP5A, PARP1, Bcl-2, JAK2, CDK4). By interacting with these targets, effective amino acid residues and binding parameter values in the binding site were determined. © The Tunisian Chemical Society and Springer Nature Switzerland AG 2024.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/11866Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1007/s42250-024-00893-7Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorBayar, Irem
dc.contributor.authorTurkmenoglu, Burçin
dc.contributor.authorAkkoc, Senem
dc.date.accessioned2026-10-18T20:26:51.554622893Z
dc.date.available2026-10-18T20:26:51.554622893Z
dc.date.issued2024
dc.description.abstractTwo 1,2-disubstituted benzimidazole-based compounds (2 and 3) were synthesized in this study. The antiproliferative activities of these compounds 1-(4-methylbenzyl)-2-p-tolyl-1H-benzo[d]imidazole (2), 1-(3-methoxybenzyl)-2-p-tolyl-1H-benzo[d]imidazole (3) together with cisplatin as a positive control drug were performed by the MTT method against the MDA-MB-231 breast cancer cell line. Compound 2 exhibited relatively higher cytotoxic activity. Molecular docking studies of compounds were performed against five breast cancer targets (PARP5A, PARP1, Bcl-2, JAK2, CDK4). By interacting with these targets, effective amino acid residues and binding parameter values in the binding site were determined. © The Tunisian Chemical Society and Springer Nature Switzerland AG 2024.
dc.description.sponsorshipThe authors would like to thank Erzincan Binali Y\u0131ld\u0131r\u0131m University, Basic Sciences Application and Research Center (EBYU-EUTAM) for the Schr\u00F6dinger Maestro 2021-2 program. SA would like to thank Suleyman Demirel University Research Fund (TSG-2021-8458) for financial support.
dc.identifier.doi10.1007/s42250-024-00893-7
dc.identifier.endpage2352
dc.identifier.issn2522-5758
dc.identifier.issue5
dc.identifier.scopus2-s2.0-85184174452
dc.identifier.startpage2345
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/11866
dc.identifier.volume7
dc.language.isoen
dc.publisherSpringer Science and Business Media Deutschland GmbH
dc.relation.ispartofChemistry Africa
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBenzimidazole
dc.subjectCytotoxic Activity
dc.subjectMolecular Docking
dc.titleBiological and in Silico Studies on the Benzimidazole-Based Compounds
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus4
rdl.source.indexSCOPUS